Results 151 to 160 of about 1,694,406 (363)
Objectives Evaluate the efficacy and safety of baricitinib in paediatric patients with active JIA‐U or chronic anterior ANA‐positive uveitis, who had an inadequate response to MTX or bDMARDs. Methods JUVE‐BRIGHT was an open‐label, active‐controlled, Phase‐3 multicentre trial which utilized a novel design, including 1:1 randomization to an active ...
Athimalaipet V. Ramanan +7 more
wiley +1 more source
Objective Recent inflammatory bowel disease (IBD) treatment guidelines have recommended against nonsteroidal anti‐inflammatory drug (NSAID) use despite prevalent musculoskeletal symptoms and opioid overuse in this population. Given the discordance between changing national guidelines and potential clinical utility, we sought to assess national temporal
Adam S. Mayer +5 more
wiley +1 more source
Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment
Objective Lupus nephritis (LN) management remains challenging, and novel noninvasive biomarkers are needed. This study quantified serum soluble mediators in the Accelerating Medicines Partnership (AMP) LN cohort to identify biomarkers of histologic features and treatment response.
Andrea Fava +48 more
wiley +1 more source
Current therapies for systemic lupus erythematosus that target a particular factor or cell type exhibit limited effectiveness. To address this limitation, our focus was on CD132, a subunit common to six inflammatory factor receptors implicated in SLE ...
Huiqi Yin +11 more
doaj +1 more source
Objective Ultrasound (US) has been proposed as a potential tool for assessing skin fibrosis in systemic sclerosis (SSc). However, a large‐scale comparison of US‐based assessment with histologic markers of skin fibrosis has not been reported. We evaluated US‐based skin assessments for their face validity (differentiation between involved SSc and healthy
Ruhani Desai +12 more
wiley +1 more source
An Attenuated Vaccine Virus of the Neethling Lineage Protects Cattle against the Virulent Recombinant Vaccine-like Isolate of the Lumpy Skin Disease Virus Belonging to the Currently Established Cluster 2.5 [PDF]
Irina Shumilova +8 more
openalex +1 more source
SANDHQFF DISEASE: INCREASED β-D-N-ACETYLGLUCOSAMINIDASE ACTIVITY AFTER CORTICOSTEROID EXPOSURE IN CULTIVATED SKIN FIBROBLASTS [PDF]
Serge B. Melançon +3 more
openalex +1 more source
Objective There are no US Food and Drug Administration–approved therapies for Raynaud phenomenon (RP) in the United States. Clinical trials have been challenged by study design. Important advances in RP patient‐reported outcome measures and mechanistic quantification allow RP‐related pain characterization.
Tracy M. Frech +4 more
wiley +1 more source
Objective A patient‐centered approach for chronic disease management, including systemic lupus erythematosus (SLE), aligns treatment with patients’ values and preferences, leading to improved outcomes. This paper summarizes how patient experiences, perspectives, and priorities informed the American College of Rheumatology (ACR) 2024 Lupus Nephritis (LN)
Shivani Garg +20 more
wiley +1 more source
Background Relapsing polychondritis (RP) is a rare disease defined by recurrent cartilaginous inflammation. Anti‐collagen II (anti‐Col2) antibodies have been proposed as a diagnostic biomarker for RP, but their performance characteristics are not well defined.
Karyssa Stonick +6 more
wiley +1 more source

